Head to Head Analysis: Q Biomed (OTCMKTS:QBIO) & DocGo (NASDAQ:DCGO)

Q Biomed (OTCMKTS:QBIO) and DocGo (NASDAQ:DCGO) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, risk, dividends, earnings and valuation.

Analyst Recommendations

This is a summary of recent ratings and target prices for Q Biomed and DocGo, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Q Biomed	0	0	0	0	0.00
DocGo	1	3	3	0	2.29

DocGo has a consensus target price of $2.38, suggesting a potential upside of 266.12%. Given DocGo’s stronger consensus rating and higher probable upside, analysts plainly believe DocGo is more favorable than Q Biomed.

Volatility and Risk

Q Biomed has a beta of 2.53, suggesting that its share price is 153% more volatile than the S&P 500. Comparatively, DocGo has a beta of 0.98, suggesting that its share price is 2% less volatile than the S&P 500.

Valuation & Earnings

This table compares Q Biomed and DocGo”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Q Biomed	N/A	N/A	N/A	($0.02)	N/A
DocGo	$322.20 million	0.20	-$182.40 million	($1.85)	-0.35

Q Biomed has higher earnings, but lower revenue than DocGo. DocGo is trading at a lower price-to-earnings ratio than Q Biomed, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

56.4% of DocGo shares are owned by institutional investors. 28.2% of Q Biomed shares are owned by company insiders. Comparatively, 3.8% of DocGo shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Q Biomed and DocGo’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Q Biomed	N/A	N/A	N/A
DocGo	-56.61%	-34.41%	-23.82%

Summary

Q Biomed beats DocGo on 6 of the 11 factors compared between the two stocks.

About Q Biomed

Q BioMed Inc., a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. The company offers Strontium Chloride Sr-89 and Metastron, a radiopharmaceutical therapeutic for the treatment of metastatic bone cancer pain. It is also developing Man-01, that is used for the treatment of primary open angle glaucoma; QBM-001 for rare pediatric non-verbal autism spectrum disorder; and Uttroside-B, a novel chemotherapeutic for liver cancer. Q BioMed Inc. has a partnership with Mannin Research Inc. for the development of therapeutic drugs to treat acute respiratory distress syndrome, glaucoma, kidney diseases, and others. The company was formerly known as ISMO Tech Solutions, Inc. and changed its name to Q BioMed Inc. in July 2015. Q BioMed Inc. was incorporated in 2013 and is based in New York, New York.

About DocGo

DocGo Inc. provides mobile health and medical transportation services for various health care providers in the United States and the United Kingdom. The company's transportation services include emergency response services; and non-emergency transport services comprise ambulance and wheelchair transportation services. It also offers mobile health services through its platform that are performed at home, offices, and other locations; event services, which include on-site healthcare support at sporting events and concerts; and total care management solutions comprising healthcare services and ancillary services, such as shelter. DocGo Inc. was founded in 2015 and is headquartered in New York, New York.